{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:50:53Z","timestamp":1794307853605,"version":"4.9.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"12","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2021.279232","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T03:19:16Z","timestamp":1628133556000},"page":"3198-3201","source":"Crossref","is-referenced-by-count":56,"title":["Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia"],"prefix":"10.3324","volume":"106","author":[{"given":"Etienne","family":"Crickx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Audia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Boutboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Comont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Cheminant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Oksenhendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Godeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Mahevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"32284","doi-asserted-by":"crossref","unstructured":"Audia S, Mah\u00e9vas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev. 2017; 16(6):620-632.","DOI":"10.1016\/j.autrev.2017.04.012"},{"key":"32285","doi-asserted-by":"crossref","unstructured":"Mah\u00e9vas M, Gerfaud-Valentin M, Moulis G. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia. Blood. 2016; 128(12):1625-1630.","DOI":"10.1182\/blood-2016-03-704734"},{"key":"32286","doi-asserted-by":"crossref","unstructured":"Barcellini W, Fattizzo B, Zaninoni A. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014; 124(19):2930-2936.","DOI":"10.1182\/blood-2014-06-583021"},{"key":"32287","doi-asserted-by":"crossref","unstructured":"Lonial S, Weiss BM, Usmani SZ. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016; 387(10027):1551-1560.","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"32288","doi-asserted-by":"crossref","unstructured":"Jain A, Gupta DK. Daratumumab for refractory warm autoimmune hemolytic anemia. Ann Hematol. 2021; 100(5):1351-1353.","DOI":"10.1007\/s00277-020-04063-w"},{"key":"32289","doi-asserted-by":"crossref","unstructured":"Cooling L, Hugan S. Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient. Transfusion. 2019; 59(12):3801-3802.","DOI":"10.1111\/trf.15539"},{"key":"32290","doi-asserted-by":"crossref","unstructured":"Schuetz C, Hoenig M, Moshous D. Daratumumab in lifethreatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018; 2(19):2550-2553.","DOI":"10.1182\/bloodadvances.2018020883"},{"key":"32291","doi-asserted-by":"crossref","unstructured":"Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A. Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Haematol. 2019; 187(2):e48-e51.","DOI":"10.1111\/bjh.16171"},{"key":"32292","doi-asserted-by":"crossref","unstructured":"Even-Or E, Naser Eddin A, Shadur B. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2020; 67(1):e28010.","DOI":"10.1002\/pbc.28010"},{"key":"32293","doi-asserted-by":"crossref","unstructured":"Driouk L, Schmitt R, Peters A. Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature. Mol Cell Pediatr. 2021; 8(1):5.","DOI":"10.1186\/s40348-021-00114-y"},{"key":"32294","doi-asserted-by":"crossref","unstructured":"Zaninoni A, Giannotta JA, Gall\u00ec A. The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease. Front Immunol. 2021; 12:649441.","DOI":"10.3389\/fimmu.2021.649441"},{"key":"32295","doi-asserted-by":"crossref","unstructured":"Ostendorf L, Burns M, Durek P. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020; 383(12):1149-1155.","DOI":"10.1056\/NEJMoa2023325"},{"key":"32296","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113(11):2386-2393.","DOI":"10.1182\/blood-2008-07-162503"},{"key":"32297","doi-asserted-by":"crossref","unstructured":"Michel M, Terriou L, Roudot-Thoraval F. A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study). Am J Hematol. 2017; 92(1):23-27.","DOI":"10.1002\/ajh.24570"},{"key":"32298","doi-asserted-by":"crossref","unstructured":"Dossier C, Prim B, Moreau C. A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome. Pediatr Nephrol. 2021; 36(5):1175-1182.","DOI":"10.1007\/s00467-020-04811-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279232\/73601","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279232\/73904","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10358\/73601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:10Z","timestamp":1794045610000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279232","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,5]]}}}